Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vanguard Total International Bond Index Fund ETF (BNDX) vs Moderna, Inc. (MRNA) Price & Performance

Vanguard Total International Bond Index Fund ETFTrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

Vanguard Total International Bond Index Fund ETF vs Moderna, Inc. — how do they compare? Vanguard Total International Bond Index Fund ETF trades at $47.81, while Moderna, Inc. trades at $63.65 (market cap $24.18B). The key difference: Moderna, Inc. is trading nearer its 52-week high, Vanguard Total International Bond Index Fund ETF nearer its low. Which is the better fit depends on your goals.

BNDXMRNA
52-Week High
$49.91$81.80
52-Week Low
$47.57$22.36
Market Cap
$24.18B
Sector
Health
Enterprise Value
$20.33B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vanguard Total International Bond Index Fund ETF

BNDX trades at $47.82, up 0.06% on the day, amid a bearish technical signal with moving averages indicating selling pressure and oscillators neutral. Recent news highlights institutional activity, including Apella Capital reducing its stake and Archer Investment Management increasing holdings. The fund's dividend schedule shows consistent payouts, with the latest dividend of $0.12 scheduled for payment in August 2026.

The outlook for BNDX is cautious due to bearish technical indicators and mixed institutional sentiment. Risks include interest rate volatility and inflation concerns, as highlighted by recent Treasury yield movements. Opportunities lie in its role as a bond ETF providing diversified international fixed income exposure, but investors should weigh macroeconomic factors affecting bond markets.

Moderna, Inc.

Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.

The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.

Returns comparison

Trailing returns across standard periods

About Vanguard Total International Bond Index Fund ETF

The fund employs an indexing investment approach designed to track the performance of the Bloomberg Global Aggregate ex-USD Float Adjusted RIC Capped Index (USD Hedged). This index provides a broad-based measure of the global, investment-grade, fixed-rate debt markets. It is non-diversified.

Read more on BNDX

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA